gRNA Market (By Product & Services: Products, Custom gRNA Synthesis Services; By gRNA Type: Research-Use; By Application; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global gRNA market size was estimated at around USD 497.93 million in 2023 and it is projected to hit around USD 2,748.61 million by 2033, growing at a CAGR of 18.63% from 2024 to 2033. The gRNA market is driven by an increasing demand for precision medicine, advancements in CRISPR technology, expanding applications of grna in therapeutics, and focus on ethical and regulatory considerations.

Key Pointers

• North America led the market with the largest market share of 53% in 2023.
• Asia Pacific region is predicted to grow at the remarkable CAGR from 2024 to 2033.
• By Product & Services, the product segment held the largest revenue share of 74% in 2023.
• By Product & Services, the custom gRNA synthesis services segment is estimated to register the fastest CAGR over the forecast period.
• By gRNA Type, the research-use segment had the largest market share in 2023.
• By Application, the genome engineering segment generated the maximum market share in 2023.
• By End-use, the pharmaceutical and biotechnology companies segment held the largest revenue share

gRNA Market Overview

The global gRNA (guide RNA) market is witnessing significant growth and evolving as a pivotal player in the field of genetic engineering and gene editing technologies. This overview aims to delve into the key aspects shaping the gRNA market, including current trends, market dynamics, and potential opportunities.

gRNA Market Growth

The exponential growth of the gRNA (guide RNA) market can be attributed to several key factors. First and foremost, the escalating demand for precision medicine has fueled the adoption of advanced gene editing tools, with gRNA playing a pivotal role in achieving targeted genetic modifications. The continuous evolution of CRISPR technology, marked by ongoing advancements in gRNA design and delivery methods, has significantly enhanced the overall efficiency and specificity of gene editing processes. Additionally, the expanding applications of gRNA in therapeutics, particularly in addressing genetic disorders, cancer, and infectious diseases, contribute to the market's robust growth. The surge in research and development activities, with substantial investments from both academic institutions and biotechnology companies, further propels innovation in gRNA applications, synthesis, and delivery systems. As customization gains prominence through tailored gRNA synthesis services, and collaborative efforts between industry players and research institutions increase, the gRNA market is poised for sustained growth. Ethical considerations and the establishment of regulatory frameworks also play a crucial role in ensuring the responsible and safe utilization of gRNA, contributing to the overall positive trajectory of the market.

Report Scope of the gRNA Market

gRNA Market Dynamics

What are the Drivers of gRNA Market?

• Precision Medicine Demand: The surge in demand for precision medicine is a major driver for the gRNA market. As personalized healthcare becomes increasingly prominent, the need for sophisticated gene editing tools like gRNA grows to facilitate precise and targeted genetic modifications.
• Advancements in CRISPR Technology: The continual progress in CRISPR technology serves as a key driver for the gRNA market. Ongoing developments in CRISPR techniques, including improvements in gRNA design and delivery, significantly enhance the efficiency and accuracy of gene editing processes.

What are the Restraints of gRNA Market?

• Ethical Concerns and Regulatory Uncertainties: The gRNA market faces challenges related to ethical concerns and regulatory uncertainties. The ethical implications of gene editing, including the potential for unintended consequences and off-target effects, raise questions about the responsible use of gRNA. Lack of clear regulatory frameworks adds an additional layer of complexity, impacting the market's growth trajectory.
• Off-Target Effects and Specificity Issues: Despite advancements, concerns persist regarding off-target effects and specificity issues associated with gRNA. The potential for unintended genetic modifications outside the target region poses a restraint on the widespread adoption of gRNA, especially in therapeutic applications where precision is paramount.

What are the Opportunities of gRNA Market?

• Focus on Agricultural and Industrial Applications: Beyond healthcare, opportunities arise in the application of gRNA in agriculture and industry. Harnessing gene editing technologies for crop improvement, biofuel production, and industrial processes opens new frontiers, providing avenues for companies to diversify and contribute to sustainable practices.
• International Market Expansion: Opportunities for market expansion exist on a global scale. As awareness and acceptance of gene editing technologies grow worldwide, companies can explore entering new markets, collaborating with international partners, and adapting their strategies to cater to diverse regulatory environments and regional needs.

Product & Services Insights

The product segment held the largest revenue share of 74% in 2023. Renowned for their exceptional accuracy, efficiency, and specificity in gene editing, these products have garnered significant popularity among researchers. Beyond products, the market also presents an array of services encompassing gRNA design, synthesis, and delivery. These services empower researchers to tailor their gene editing experiments with bespoke gRNA sequences and delivery systems, ultimately enhancing precision and specificity. The widespread availability and elevated purity of these products stand out as the primary factors driving the dominance of this segment.

Custom gRNA synthesis services segment is estimated to register the fastest CAGR over the forecast period. These services are offered by biotechnology companies specializing in gene editing technologies and provide a range of options for researchers to design & order custom gRNAs that meet their specific experimental needs. Thus, propelling the segment growth.

gRNA Type Insights

In 2023, the research-use segment had the largest market share. This dominance can be attributed to the heightened demand for research-grade gRNA, driven by extensive research programs conducted across diverse research institutes. The segment's stronghold is expected to persist throughout the forecast period, propelled by the increasing applications of gRNA in clinical research. Furthermore, the widespread adoption of CRISPR/Cas9 technology, a prevalent gene-editing tool, is contributing to the escalating demand for gRNA within the research-use segment.

Anticipated to exhibit the swiftest CAGR over the forecast period is the GMP-grade segment. This segment emphasizes the production of gRNA under rigorous quality control and regulatory guidelines, specifically tailored for deployment in clinical trials and patient treatment. The enforcement of Good Manufacturing Practices (GMP) ensures consistent and controlled manufacturing, accompanied by high levels of quality assurance. This stringent approach is particularly crucial in medical applications, where safety and efficacy take precedence. The availability of GMP-grade gRNA products is poised to play a pivotal role in propelling the gene editing market, particularly within the realm of personalized medicine.

Application Insights

In 2023, the genome engineering segment generated the maximum market share, and is projected to exhibit the fastest Compound Annual Growth Rate (CAGR) during the forecast period. Genome engineering stands out as a highly lucrative application for gRNA, given its transformative impact across diverse industries. The precision and adaptability of gRNA within CRISPR-based editing have brought about a revolutionary shift in genetic modifications, unlocking substantial opportunities in medicine, agriculture, and biotechnology.

The role of gRNA in genome engineering is particularly pivotal in synthetic biology, enabling the design and construction of artificial biological systems. This capability proves invaluable in industrial biotechnology, facilitating the optimization of microbial strains for the enhanced production of biofuels, pharmaceuticals, and various other bioproducts. This, in turn, amplifies the demand for genome engineering, thereby propelling the overall market growth.

End-use Insights

In 2022, the pharmaceutical and biotechnology companies segment held the largest revenue share. The widespread adoption of gRNA in precision medicine by pharmaceutical and biotech firms is a driving force behind its market dominance, becoming integral to the development of personalized therapies. Biotechnology companies leverage gRNA for optimizing bioproduction processes, including the development of cell lines for biotherapeutic production. The integration of gRNA in bioproduction applications contributes significantly to process efficiency, ultimately reducing production timelines and costs.

The academic research institutes segment is anticipated to register the fastest CAGR over the forecast period. Academic researchers extensively employ gRNA to investigate gene functions, explore biological mechanisms, and make fundamental discoveries in molecular biology. The constant demand for advanced tools like gRNA in academic research serves as a catalyst for market growth, reflecting the ongoing pursuit of innovative solutions by researchers in their studies and thereby bolstering the overall market expansion.

Regional Insights

In 2023, North America dominated the market with the largest market share of 53%. This leadership is attributed to various factors, including the substantial local presence of key players like Thermo Fisher Scientific and Merck KGaA. The region also witnessed a surge in research and development spending by these key players, fostering the growth of the gRNA industry. An illustrative example of this growth is the collaboration between Thermo Fisher Scientific, Inc. and Pfizer, Inc. in May 2022, aiming to expand access to Next-Generation Sequencing (NGS)-based testing for cancer patients. The initial focus on lung and breast cancer is expected to drive increased demand for gRNAs targeting genes associated with these specific cancers.

The Asia Pacific region is predicted to grow at the remarkable CAGR during the forecast period. This anticipated growth is fueled by factors such as a significant target population, rapid adoption of various technologies, the presence of numerous startups, developing healthcare infrastructure, and high unmet clinical needs. These factors collectively offer substantial growth opportunities for key manufacturers in the region.

Key Companies:

• Thermo Fisher Scientific Inc.
• Agilent Technologies Inc.
• System Biosciences, LLC.
• Jena Bioscience GmbH
• Merck KGaA
• GENEWIZ (Azenta Life Sciences)
• Takara Bio Inc.
• Synbio Technologies
• Horizon Discovery Ltd.
• Synthego

gRNA Market Segmentations:

By Product & Services

• Products
  • gRNA Final Products
  • gRNA Synthesis Products
    • gRNA Synthesis Kits
    • Plasmids
    • Others
• Custom gRNA Synthesis Services

By gRNA Type

• Research-Use
• GMP-grade

By Application

• Genome Engineering
• Disease Model Studies
• Functional Genomics
• Epigenetics
• Others

By End-use

• Pharmaceutical & Biotechnology Companies
• Academic Research Institutes
• CMOs & CROs

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa